VCBeat Health
Contact Us
Home
China Healthcare Select
Insights
MNC China Lens
Vertical Industries
Services
Partnership Development
Market Entry Advisory
Ecosystem Engagement Advisory
About VCBeat
Why VCBeat
Log In
Home
Novartis Bets $12 Billion on AOC Platform as Phase I/II FSHD Trial Delivers Landmark Results
Novartis Bets $12 Billion on AOC Platform as Phase I/II FSHD Trial Delivers Landmark Results
Jun 11, 2026 18:35 CST Updated Jun 12, 02:17
Share:
